Background: GPM6A Biology and Significance

Glycoprotein M6A (GPM6A) is a four-transmembrane domain protein belonging to the proteolipid protein (PLP) superfamily. It is predominantly expressed in neurons of the central nervous system (CNS) and plays critical roles in neuronal plasticity, filopodium formation, and synaptogenesis. GPM6A is involved in the regulation of membrane microdomain organisation and has been implicated in stress responses, neurodevelopmental disorders, and psychiatric conditions including schizophrenia and major depressive disorder.

As a heavily glycosylated integral membrane protein, GPM6A interacts with cytoskeletal components and signalling molecules, facilitating neurite outgrowth and dendritic spine development. The recombinant form of Human GPM6A enables researchers to study these interactions under controlled in vitro conditions without the complexity of native tissue extracts.

Reconstitution and Handling Protocol

Materials required: Sterile deionised water or the buffer recommended on the product-specific datasheet, low-protein-binding microcentrifuge tubes, ice bath.

1. Equilibrate to room temperature: Allow the vial containing lyophilised Recombinant Human GPM6A Protein to equilibrate to room temperature (18–25 °C) for approximately 10 minutes before opening. This minimises moisture condensation inside the vial.
2. Reconstitute: Add the volume of sterile reconstitution buffer specified on the product datasheet (typically sterile PBS or water, pH 7.4) gently along the inner wall of the vial. Do not inject directly onto the lyophilised cake to avoid foaming and protein denaturation.
3. Gentle mixing: Gently swirl or roll the vial for 1–2 minutes. Do NOT vortex. Allow the solution to stand for 5 minutes at room temperature to ensure complete dissolution.
4. Centrifuge briefly: Spin the reconstituted solution at low speed (approximately 300–500 × g, 1 minute) to collect any liquid from the vial walls and remove insoluble particulates.
5. Aliquot immediately: Divide the reconstituted protein into single-use aliquots in low-protein-binding tubes to avoid repeated freeze-thaw cycles. Snap-freeze aliquots in liquid nitrogen or dry ice/ethanol bath before long-term storage.

Note: Specific reconstitution volumes, buffer compositions, and protein concentrations are stated on the Certificate of Analysis (CoA) and product datasheet supplied with each lot. Always refer to these documents for lot-specific instructions.

Storage Conditions and Stability

Lyophilised (dry) form: Store at -20 °C for routine use or at -80 °C for long-term storage. Under these conditions, lyophilised recombinant proteins are typically stable for 12–24 months from the date of manufacture. Avoid exposure to moisture; use desiccant if necessary.

Reconstituted (liquid) form: Once reconstituted, aliquot and store at -80 °C. Working aliquots may be kept at 4 °C for up to 1 week. Repeated freeze-thaw cycles will degrade protein activity and structural integrity; therefore, single-use aliquoting is strongly recommended.

Carrier protein addition: For long-term stability of the reconstituted protein at low concentrations, the addition of a carrier protein (e.g., 0.1–0.5% bovine serum albumin, BSA) may be considered, unless carrier protein interference is a concern for the intended assay. Consult the product datasheet for specific recommendations.

Tip: Label all aliquots with protein name, concentration, reconstitution date, and freeze-thaw cycle number.

Recommended Experimental Applications

Recombinant Human GPM6A Protein is suitable for multiple in vitro research applications. The following are common uses; researchers should optimise conditions for their specific experimental system:

• SDS-PAGE and Western Blot: Use as a positive control or molecular weight standard to confirm antibody specificity against GPM6A. Load the recommended protein mass per lane as indicated on the datasheet.
• ELISA: Employ as a coating antigen for the development or validation of anti-GPM6A antibody-based immunoassays.
• Protein–Protein Interaction Studies: Use in pull-down assays or co-immunoprecipitation experiments to identify binding partners of GPM6A within neuronal signalling pathways.
• Functional/Cell-Based Assays: Recombinant GPM6A may be used to investigate filopodium induction, neurite outgrowth, and membrane microstructure dynamics in cell culture models. Confirm bioactivity data on the product-specific CoA before use.
• Antibody Production and Screening: Suitable as an immunogen for raising and characterising anti-GPM6A antibodies in research settings.

Note: Always determine the optimal protein concentration, incubation time, and buffer conditions empirically for each application.

Quality Control and Purity

Each lot of Recombinant Human GPM6A Protein (rp369837) from Aladdin Scientific is subject to quality control testing prior to release. Standard QC assessments for recombinant proteins typically include:

• Purity: Assessed by SDS-PAGE under reducing and/or non-reducing conditions; purity specification is provided on the lot-specific CoA.
• Identity: Confirmed by Western blot using a validated anti-GPM6A antibody or by mass spectrometry.
• Endotoxin level: Tested by Limulus Amebocyte Lysate (LAL) assay; the endotoxin specification is stated on the CoA.
• Bioactivity: Functional activity may be assessed by a cell-based assay; refer to the CoA for lot-specific activity data.

Researchers are advised to request and review the CoA and Safety Data Sheet (SDS) for each lot received. Contact Aladdin Scientific technical support if any quality concerns arise.